Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development
The current Coronavirus Disease 2019 (COVID-19) pandemic is causing great alarm around the world. The pathogen for COVID-19 – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – is the seventh known coronavirus to cause pneumonia in humans. While much remains unknown about SARS-CoV-2, phy...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1787068 |
| _version_ | 1797677300381122560 |
|---|---|
| author | Sayeh Ezzikouri Jalal Nourlil Soumaya Benjelloun Michinori Kohara Kyoko Tsukiyama-Kohara |
| author_facet | Sayeh Ezzikouri Jalal Nourlil Soumaya Benjelloun Michinori Kohara Kyoko Tsukiyama-Kohara |
| author_sort | Sayeh Ezzikouri |
| collection | DOAJ |
| description | The current Coronavirus Disease 2019 (COVID-19) pandemic is causing great alarm around the world. The pathogen for COVID-19 – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – is the seventh known coronavirus to cause pneumonia in humans. While much remains unknown about SARS-CoV-2, physicians and researchers have begun to publish relevant findings, and much evidence is available on coronaviruses previously circulating in human and animal populations. In this review, we situate COVID-19 in its context as a transboundary viral disease, and provide a comprehensive discussion focused on the discovery, spread, virology, pathogenesis, and clinical features of this disease, its causative coronaviral pathogen, and approaches to combating the disease through immunotherapies and other treatments and vaccine development. An epidemiological survey revealed a potentially large number of asymptomatic SARS-CoV-2 carriers within the population, which may hamper efforts against COVID-19. Finally, we emphasize that vaccines against SARS-CoV-2, which may be developed by 2021, will be essential for prevention of COVID-19. |
| first_indexed | 2024-03-11T22:42:44Z |
| format | Article |
| id | doaj.art-bef6b860e5eb4d4c92b129bb8b603de8 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:42:44Z |
| publishDate | 2020-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-bef6b860e5eb4d4c92b129bb8b603de82023-09-22T08:51:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-12-0116122992300010.1080/21645515.2020.17870681787068Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine developmentSayeh Ezzikouri0Jalal Nourlil1Soumaya Benjelloun2Michinori Kohara3Kyoko Tsukiyama-Kohara4Institut Pasteur Du MarocInstitut Pasteur Du MarocInstitut Pasteur Du MarocThe Tokyo Metropolitan Institute of Medical ScienceKagoshima UniversityThe current Coronavirus Disease 2019 (COVID-19) pandemic is causing great alarm around the world. The pathogen for COVID-19 – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – is the seventh known coronavirus to cause pneumonia in humans. While much remains unknown about SARS-CoV-2, physicians and researchers have begun to publish relevant findings, and much evidence is available on coronaviruses previously circulating in human and animal populations. In this review, we situate COVID-19 in its context as a transboundary viral disease, and provide a comprehensive discussion focused on the discovery, spread, virology, pathogenesis, and clinical features of this disease, its causative coronaviral pathogen, and approaches to combating the disease through immunotherapies and other treatments and vaccine development. An epidemiological survey revealed a potentially large number of asymptomatic SARS-CoV-2 carriers within the population, which may hamper efforts against COVID-19. Finally, we emphasize that vaccines against SARS-CoV-2, which may be developed by 2021, will be essential for prevention of COVID-19.http://dx.doi.org/10.1080/21645515.2020.1787068human coronaviruspublic healthrespiratory virusesoriginpathogenesissars-cov-2 |
| spellingShingle | Sayeh Ezzikouri Jalal Nourlil Soumaya Benjelloun Michinori Kohara Kyoko Tsukiyama-Kohara Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development Human Vaccines & Immunotherapeutics human coronavirus public health respiratory viruses origin pathogenesis sars-cov-2 |
| title | Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development |
| title_full | Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development |
| title_fullStr | Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development |
| title_full_unstemmed | Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development |
| title_short | Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development |
| title_sort | coronavirus disease 2019 historical context virology pathogenesis immunotherapy and vaccine development |
| topic | human coronavirus public health respiratory viruses origin pathogenesis sars-cov-2 |
| url | http://dx.doi.org/10.1080/21645515.2020.1787068 |
| work_keys_str_mv | AT sayehezzikouri coronavirusdisease2019historicalcontextvirologypathogenesisimmunotherapyandvaccinedevelopment AT jalalnourlil coronavirusdisease2019historicalcontextvirologypathogenesisimmunotherapyandvaccinedevelopment AT soumayabenjelloun coronavirusdisease2019historicalcontextvirologypathogenesisimmunotherapyandvaccinedevelopment AT michinorikohara coronavirusdisease2019historicalcontextvirologypathogenesisimmunotherapyandvaccinedevelopment AT kyokotsukiyamakohara coronavirusdisease2019historicalcontextvirologypathogenesisimmunotherapyandvaccinedevelopment |